In this report, the Targeted DNA/RNA Sequencing Market has been segmented by Technology, Workflow, Application, Type, End Use and Geography.

Targeted DNA/RNA Sequencing Market, Segmentation by Workflow

The Targeted DNA/RNA Sequencing Market has been segmented by Workflow into Pre-sequencing, Sequencing and Data Analysis.

Pre-sequencing

Pre-sequencing accounts for approximately 35% of the targeted DNA/RNA sequencing market. This step involves sample preparation, library construction, and target enrichment to ensure high-quality sequencing data. Advancements in automation and workflow optimization are driving growth.

Sequencing

Sequencing represents about 45% of the market. This stage covers the actual generation of sequence data using platforms like next-generation sequencing (NGS). Increased adoption of high-throughput sequencers and cost reduction in sequencing technologies are key drivers.

Data Analysis

Data analysis contributes approximately 20% of the market. This critical phase involves bioinformatics tools and computational platforms to interpret sequencing results. The rising integration of AI-driven analytics and cloud-based solutions supports growth in this segment.

Targeted DNA/RNA Sequencing Market, Segmentation by Type

The Targeted DNA/RNA Sequencing Market has been segmented by Type into DNA Based Targeted Sequencing and RNA Based Targeted Sequencing.

DNA Based Targeted Sequencing

DNA based targeted sequencing accounts for approximately 65% of the market. This approach focuses on specific genomic regions for applications such as cancer genomics, inherited disease screening, and pharmacogenomics. Advancements in target enrichment methods are driving growth in this segment.

RNA Based Targeted Sequencing

RNA based targeted sequencing represents about 35% of the market. This technique allows for the identification of gene expression profiles and fusion transcripts in research and clinical applications. The increasing demand for transcriptome profiling and liquid biopsy is boosting market expansion.

Targeted DNA/RNA Sequencing Market, Segmentation by Application

The Targeted DNA/RNA Sequencing Market has been segmented by Application into Human Biomedical Research, Plant & Animal Sciences, Drug Discovery and Others.

Human Biomedical Research

Human biomedical research accounts for approximately 50% of the targeted DNA/RNA sequencing market. This segment is driven by clinical applications such as cancer genomics, genetic disease research, and personalized medicine. Increasing adoption of next-generation sequencing technologies supports growth.

Plant & Animal Sciences

Plant and animal sciences represent about 20% of the market. Targeted sequencing helps in crop improvement, breeding programs, and veterinary genomics. Growing focus on food security and sustainable agriculture drives this segment’s expansion.

Drug Discovery

Drug discovery contributes approximately 20% of the market. This application utilizes targeted sequencing to identify biomarkers, evaluate drug responses, and optimize clinical trial design. The rising demand for precision therapeutics fuels this segment.

Others

Others account for around 10% of the market, including applications in forensics, microbial genomics, and environmental monitoring. Advancements in sequencing workflows and bioinformatics tools support growth in this diverse segment.

Targeted DNA/RNA Sequencing Market, Segmentation by End Use

The Targeted DNA/RNA Sequencing Market has been segmented by End Use into Academic Research, Hospitals & Clinics, Pharma & Biotech Entities and Other.

Academic Research

Academic research accounts for approximately 40% of the targeted DNA/RNA sequencing market. This segment benefits from rising funding for genomics and biomedical research. The increasing use of sequencing technologies in universities and research institutions drives growth.

Hospitals & Clinics

Hospitals and clinics represent about 30% of the market. These end users adopt targeted sequencing for diagnostics, personalized medicine, and oncology applications. Growing focus on precision healthcare and integrated sequencing platforms supports expansion.

Pharma & Biotech Entities

Pharma and biotech entities contribute around 20% of the market. They leverage targeted sequencing for drug discovery, clinical trials, and biomarker validation. Increasing collaboration between biotech firms and academic institutions is boosting this segment.

Other

The 'Other' category holds about 10% of the market, including applications in forensic science, veterinary research, and environmental genomics. Technological advancements in sequencing solutions and bioinformatics integration drive growth.

Targeted DNA/RNA Sequencing Market, Segmentation by Geography

In this report, the Targeted DNA/RNA Sequencing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Targeted DNA/RNA Sequencing Market Share (%), by Geographical Region

North America

North America holds approximately 40% of the targeted DNA/RNA sequencing market, driven by strong R&D investments, advanced biotech infrastructure, and high adoption of next-generation sequencing technologies. The presence of leading genomics companies further supports growth.

Europe

Europe accounts for around 30% of the market, supported by robust biomedical research programs and favorable regulatory policies. Increasing collaboration between academia and biopharma firms enhances the regional market.

Asia Pacific

Asia Pacific contributes about 20% of the market, driven by rising healthcare investments and expansion of genomic research initiatives. Countries such as China and India play a pivotal role in regional growth.

Middle East and Africa

Middle East and Africa hold around 5% of the market. Increased government focus on genomic medicine and the development of biotech hubs contribute to the growing demand for targeted sequencing solutions.

Latin America

Latin America represents approximately 5% of the market, led by countries like Brazil and Mexico. Rising investments in genomic research and increasing healthcare awareness support market growth.

This report provides an in depth analysis of various factors that impact the dynamics of Targeted DNA/RNA Sequencing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Targeted SSI prevention strategies emerging
• Tailored care plans improve outcomes

• Better microbial profiling with new tech - The ability to achieve better microbial profiling with new technologies is a key driver for the targeted DNA/RNA sequencing market. Innovations in sequencing platforms, such as next-generation sequencing (NGS), microfluidics, and enhanced library preparation kits, have significantly improved the sensitivity and specificity of detecting diverse microbial communities. These advancements enable researchers and clinicians to perform precise, high-throughput analysis of microbial genomes, even at low abundance, leading to better understanding of infections, resistance patterns, and host-microbe interactions.

  Accurate microbial profiling is essential for applications in infectious disease diagnostics, personalized medicine, epidemiology, and environmental microbiology. New technologies allow for rapid identification of pathogens, antibiotic resistance genes, and microbial biomarkers, supporting targeted treatments and outbreak control. As the demand for precision microbiome analysis grows across research and clinical settings, the adoption of targeted DNA/RNA sequencing platforms is expected to accelerate, driving strong market growth.

Restraints

• High Initial Investment Costs
• Complex Data Analysis and Interpretation
• Data Privacy and Security Concerns

• Regulatory Challenges and Compliance Requirements - Regulatory challenges and compliance requirements present a significant restraint on the targeted DNA/RNA sequencing market. Sequencing technologies used in clinical and diagnostic settings must adhere to stringent regulations concerning data accuracy, validation procedures, and patient safety. Gaining approval from agencies such as the FDA, EMA, or equivalent regulatory bodies can be time-consuming and costly, particularly when introducing new platforms or updating existing protocols for clinical use.

  Additionally, compliance with data privacy laws, quality assurance standards, and laboratory certifications adds operational complexity for sequencing providers. The need to navigate different regional and national regulatory frameworks can delay market entry and hinder international expansion. These challenges are particularly burdensome for startups and smaller labs that lack dedicated regulatory teams, limiting innovation and reducing the pace of commercial adoption in some segments of the market.

Opportunities

• Expansion of Precision Medicine Initiatives
• Integration of Genomic Data into Clinical Practice
• Development of Companion Diagnostics

• Adoption of Liquid Biopsies for Non-invasive Testing - The increasing adoption of liquid biopsies for non-invasive testing is creating major opportunities for the targeted DNA/RNA sequencing market. Liquid biopsies allow for the detection of circulating tumor DNA (ctDNA), cell-free RNA, and other biomarkers from blood samples, offering a less invasive, repeatable alternative to tissue biopsies. Targeted sequencing plays a vital role by providing the sensitivity and precision needed to identify genetic mutations and expression profiles that guide diagnosis and treatment.

  This approach is gaining traction in oncology, prenatal testing, and chronic disease monitoring, where early detection and real-time insights are critical. As healthcare systems move toward precision medicine and personalized care, the combination of liquid biopsy and targeted sequencing enables faster, more accurate clinical decisions. The growing use of this technology in clinical practice and research is expected to drive sustained market expansion globally.

Key players in Targeted DNA/RNA Sequencing Market include;

• Illumina, Inc.
• F. Hoffmann-La Roche Ltd
• Agilent Technologies
• PierianDx
• Genomatix GmbH
• GATC Biotech Ag
• Oxford Nanopore Technologies
• Macrogen, Inc.
• Thermo Fisher Scientific
• QIAGEN

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis